A Phase 2 interventional study of Abatacept in Graft Versus Host Disease, sponsored by Emory University. Active, not recruiting at 9 sites in United States. Open to participants aged Up to 20 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Emory University · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing abatacept in Graft vs Host Disease — 3 open to participants now, 6 under way, none of them phase 3. Abatacept · Graft vs Host Disease.
Among the 10 studies testing abatacept in Graft vs Host Disease, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 2, and was the 5th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.
Browse Graft vs Host Disease studies →3 of the 10 studies testing abatacept in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 2+
Northwell Health · Sites in United States
Ages 14–100
Peking University People's Hospital
Ages 14+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: Up to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9
First in 2013; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 50 across the 10 interventional studies. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 6 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
4 of the studies testing abatacept in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05621759NYU Langone HealthCyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD | 2027-01-30 |
| NCT03924401Emory UniversityAcute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant | 2027-03-01 |
| NCT04380740Boston Children's HospitalExtended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis | 2027-05 |
| NCT05289167Northwell HealthPost-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies testing abatacept in Graft vs Host Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will see if extended abatacept administration (combined with a standard regimen of tacrolimus and mycophenolate mofetil) will prevent acute and chronic graft-versus-host disease (GVHD) in children and adolescents receiving unrelated donor (URD) hematopoietic stem cell transplantation (HSCT), without compromising their engraftment or reconstitution of protective immunity to infection.
The study will enroll 30 pediatric patients with serious non-malignant hematologic diseases (NMHD) undergoing URD HSCT. The trial will include patients with 7/8 donors and those with 8/8 (matched) donors. All participants will receive 8 doses of abatacept. Recruitment is expected to last for about 2 years and participants will be followed for up to 3 years.
Many serious non-malignant hematologic diseases (NMHD) affecting children, including severe aplastic anemia (SAA), Fanconi anemia (FA), sickle cell disease (SCD), and thalassemia can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). While the best results are achieved with HSCT from human leukocyte antigen (HLA)-matched siblings, most children lack such donors, and many children with NMHD are therefore transplanted with grafts from an adult unrelated donor (URD). Because URD grafts are less histocompatible, they are more likely to cause GVHD, a process driven by the reaction of donor T cells against incompatible host tissues. Despite the routine administration of immune suppression for GVHD prophylaxis, GVHD claims the lives of many and plagues others with incapacitating chronic illness. For NMHD, the threat of GVHD limits the use of URD HSCT to only the most severely affected children. In African-Americans and other ethnic minorities, the situation is compounded by the fact that most of these children lack fully matched URD and typically receive mismatched and matched grafts, which carry an increased risk for graft rejection. A more effective form of GVHD prophylaxis that does not compromise engraftment is urgently needed, both to improve outcomes for those children undergoing HSCT as well as to allow expansion of this curative therapy to the many children with NMHD who forego transplantation because of the risk for GVHD.
The researchers have investigated the use of the co-stimulation blocking agent CTLA4-Ig (abatacept) to prevent GVHD. Study results to date indicate that abatacept strongly inhibits allo-reactive donor T cells and is clinically safe and effective. The clinical experience has included a variety of recipients: children and adults, peripheral blood stem cells (PBSC) and bone marrow (BM) grafts, as well as mismatched and matched unrelated and matched related donors; all have involved the administration of four IV doses of abatacept, on days -1, +5, +14, and +28, in combination with standard calcineurin inhibitor-based GVHD prophylaxis. Collectively, the results to date suggest that this combination, including abatacept, very effectively prevents acute GVHD. However, these results also suggest that protection against chronic GVHD is more limited. In this current trial, the researchers will attempt to more effectively prevent chronic GVHD by extending the administration of abatacept, giving eight doses (additional doses days +56, +84, +112, and +150). This trial will test the hypothesis that extended abatacept administration (combined with a standard regimen of tacrolimus and mycophenolate mofetil) will effectively prevent acute and chronic GVHD in children and adolescents receiving URD HSCT, without compromising their engraftment or reconstitution of protective immunity to infection.
The ASCENT Trial is a single arm, multi-center, phase II study testing the hypothesis that extended abatacept administration (combined with a standard regimen of tacrolimus and mycophenolate mofetil) will effectively prevent acute and chronic GVHD in children and adolescents receiving URD HSCT, without compromising their engraftment or reconstitution of protective immunity to infection. The study will enroll 30 pediatric patients with serious NMHD undergoing URD HSCT. The trial will include two strata, based on donor matching. Stratum 1 will be for patients with 7/8 donors and stratum 2 will be for those with 8/8 (matched) donors. Study participants will be admitted to the hospital ten or eleven days prior to the day of transplant (day -10 or day -11) to complete a conditioning regimen to prevent the donor cells from being rejected. Patients will receive one of three reduced toxicity or intensity conditioning regimens based upon underlying disease and/or physician preference: (1) anti-thymocyte globulin, fludarabine, and a low dose of cyclophosphamide (FA patients only); (2) anti-thymocyte globulin, fludarabine, cyclophosphamide, and a low dose of total body radiation (SAA and other bone marrow failure disorders); or (3) alemtuzumab, fludarabine, melphalan, and thiotepa (hemoglobinopathy and non-SAA bone marrow failure disorders). All participants will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150). Recruitment is expected to last for about 2 years and participants will be followed for up to 3 years. Weight-based peripheral blood samples will be drawn longitudinally through two years to evaluate immune reconstitution.
The primary objective is to determine the rejection-free, severe graft-versus-host disease (GVHD)-free survival in pediatric patients with serious non-malignant hematologic diseases (NMHD) undergoing unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) with abatacept added to conventional GVHD prophylaxis. The secondary objective is to characterize the impact of abatacept on infection and the reconstitution of protective immunity to infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have one of the following diseases:
Any genotypic form of SCD with severe disease, defined as one or more of the following criteria:
Asymptomatic cerebrovascular disease, as evidenced by one the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants who are undergoing URD HSCT for serious NMHD will receive 8 doses of abatacept in addition to conventional GVHD prophylaxis.
Drug: Abatacept
All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
Also known as: Orencia
Event-free survival
Event-free survival is a composite endpoint defined as rejection-free, severe GVHD-free survival. Events for this outcome include death, severe (grade II-IV) acute GVHD up to day 100, moderate to severe chronic GVHD up to 1 year, and/or graft rejection up to 1 year.
Time frame: Up to 3 years
Cytomegalovirus (CMV) Viremia
The number of participants experiencing cytomegalovirus (CMV) viremia will be reported. CMV viremia will be defined as the occurrence of a positive polymerase chain reaction (PCR) test prior to Day 180.
Time frame: Up to Day 180
CMV Invasive Disease
The number of participants experiencing CMV invasive disease will be reported. CMV invasive disease will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures.
Time frame: Up to 2 years
Post-transplant lymphoproliferative disease (PTLD)
The number of participants experiencing post-transplant lymphoproliferative disease (PTLD) will be reported. PTLD will be defined in accordance with the World Health Organization's (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues.
Time frame: Up to 2 years
Regimen-Related Toxicity
The number of participants experiencing regimen-related toxicity (RRT) will be reported. RRT will be scored according to the Bearman scale. Major RRT, defined as grade 4 (causing death) in any organ system or grade 3 for pulmonary, cardiac, renal, oral mucosal, neurologic, or hepatic, will be recorded.
Time frame: Day 42 Post-transplant
Neutrophil Recovery
The time to neutrophil recover, in days, will be reported. Neutrophil recovery will be defined as the first of 3 consecutive days following the nadir that the absolute neutrophil count is at least 500/microliter of blood.
Time frame: Up to Day 60
Platelet Recovery
The time to platelet recover, in days, will be reported. Platelet recovery will be defined as the first day that the platelet count is at least 50,000/microliter of blood, without a transfusion in the preceding 7 days.
Time frame: Up to Day 60
Non-Engraftment
The number of participants experiencing non-engraftment will be reported. Non-engraftment will be defined as lack of neutrophil recovery, or neutrophil recovery with lack of myeloid donor chimerism.
Time frame: Day 28
Secondary Graft Failure
The number of participants experiencing secondary graft failure will be reported. Secondary graft failure will be defined by initial engraftment but subsequent development of an absolute neutrophil count (ANC) \< 500/μl for fourteen consecutive days.
Time frame: Up to 3 years
Graft Loss
The number of participants experiencing graft loss will be reported. Graft loss will be defined by initial engraftment (assessed by neutrophil recovery and donor chimerism) with the subsequent loss of donor myeloid chimerism (regardless whether persistent neutropenia develops).
Time frame: Up to 3 years
Acute GVHD
The number of participants experiencing acute GVHD (including all grades and stratified by grades) will be reported. Acute GVHD will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures.
Time frame: Up to 1 year
Chronic GVHD
The number of participants experiencing chronic GVHD (including overlap syndrome) will be reported. Chronic GVHD will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures.
Time frame: Up to 2 years
Immune Suppression-Free Survival
The number of participants experiencing immune suppression-free survival will be reported. Immune suppression-free survival is measured as participant survival while off all systemic immunosuppressive agents.
Time frame: Year 2
Immune Suppression-Free/Disease-Free Survival
The number of participants experiencing immune suppression-free/disease-free survival will be reported. Immune suppression-free/disease-free survival will be defined as rejection-free survival off all systemic immunosuppressive agents.
Time frame: Year 2
Rejection-free survival
The number of participants experiencing rejection-free survival will be reported. Rejection-free survival will be defined as survival without non-engraftment, secondary graft failure, or graft loss.
Time frame: Up to 3 years
Overall survival
The number of participants experiencing surviving at the end of the study follow up period will be reported.
Time frame: Up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2019 (actual). Primary completion is estimated for Mar 2027, 90 months after the start.
Of 86 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 116. This study's planned 90 months is above that.
Counting every sponsor, half of 103 studies reached it within 52 months; a quarter within 29 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept